Skip to main content
SpringerLink
Log in

Cinacalcet should not be used to treat secondary hyperparathyroidism in stage 3–4 chronic kidney disease

  • Viewpoint
  • Published:

From Nature Clinical Practice Nephrology

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Slatopolsky E et al. (1999) Pathogenesis of secondary hyperparathyroidism. Kidney Int Suppl 73: S14–S19

    Article  CAS  PubMed  Google Scholar 

  2. Levin A et al. (2007) Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 71: 31–38

    Article  CAS  PubMed  Google Scholar 

  3. Wolf M et al. (2007) Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 72: 1004–1013

    Article  CAS  PubMed  Google Scholar 

  4. Coyne D et al. (2006) Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD. Am J Kidney Dis 47: 263–276

    Article  CAS  PubMed  Google Scholar 

  5. Coburn JW et al. (2004) Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4. Am J Kidney Dis 43: 877–890

    Article  CAS  PubMed  Google Scholar 

  6. Goodman WG et al. (1998) Calcium-sensing by parathyroid glands in secondary hyperparathyroidism. J Clin Endocrinol Metab 83: 2765–2772

    CAS  PubMed  Google Scholar 

  7. Delmez JA et al. (1989) Parathyroid hormone suppression by intravenous 1,25-dihydroxyvitamin D: a role for increased sensitivity to calcium. J Clin Invest 83: 1349–1355

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Gunn IR and Gaffney D (2004) Clinical and laboratory features of calcium-sensing receptor disorders: a systematic review. Ann Clin Biochem 41: 441–458

    Article  CAS  PubMed  Google Scholar 

  9. Moe SM et al. (2005) Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl. Nephrol Dial Transplant 20: 2186–2193

    Article  CAS  PubMed  Google Scholar 

  10. Charytan C et al. (2005) Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis. Am J Kidney Dis 46: 58–67

    Article  CAS  PubMed  Google Scholar 

  11. US FDA (online 5 July 2004) Sensipar (Cinacalcet HCI) Tablets Approval Application No.: 021688 [http://www.fda.gov/cder/foi/nda/2004/21-688_Sensipar.htm] (accessed 24 January 2008)

  12. Health Canada (online 19 June 2007) Sensipar® no longer indicated for chronic kidney disease patients (stages 3 and 4) not receiving dialysis [http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/2007/sensipar_ hpc-cps_e.html] (accessed 22 January 2008)

  13. Ba J and Friedman PA (2004) Calcium-sensing receptor regulation of renal mineral ion transport. Cell Calcium 35: 229–237

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Author notes

  1. Washington University School of Medicine, 660 South Euclid Avenue, Campus Box 8129, St Louis, MO 63110, USA dcoyne@im.wustl.edu

Authors and Affiliations

  1. DW Coyne is Professor of Medicine at Washington University School of Medicine, St Louis, MO, USA.,

    Daniel W Coyne

Authors
  1. Daniel W Coyne
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author is a consultant, speaker, and investigator for Abbott, the maker of paricalcitol and calcitriol; an investigator for Amgen, maker of cinacalcet; and a consultant to INEOS, developer of an investigational phosphate binder.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Coyne, D. Cinacalcet should not be used to treat secondary hyperparathyroidism in stage 3–4 chronic kidney disease. Nat Rev Nephrol 4, 364–365 (2008). https://doi.org/10.1038/ncpneph0821

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpneph0821

  • Springer Nature Limited

Search

Navigation